Additional phase II studies examining regimens with atezolizumab plus bevacizumab plus platinum‐based chemotherapy have also supported similar OS outcomes in patients with NSCLC carrying EGFR mutations who had previously received a TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.